Role of Adjuvant Systemic Therapy for Stage I NSCLC

Results of trials reported in the last four years have convincingly demonstrated a role for adjuvant or postoperative chemotherapy in the management of good performance status patients after a complete resection of their stages II and IIIA non-small cell lung cancer. The role of chemotherapy after surgery of stage I disease, however, remains a subject of debate. This article reviews the limited data that pertain to this approach in early stage disease and set the stage for future trials in this population of patients.